Table 1.
Summary of patient characteristics and chromosomal imbalances detected by a conventional comparative genomic hybridization (CGH) method
| Case/cell line | Age (years) | Sex | WBC counts at Dx | NCI risk | CR | Relapse | Survival | Losses by CGH | Gains by CGH |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | M | 14 700 | SR | Y | Y | N | 6q21‐q22.1 | 10, 162 |
| 2 | 4 | M | 3 600 | SR | Y | Y | Y | None | None |
| 3 | 2 | M | 11 000 | SR | Y | N | Y | 12p11 | None |
| 4 | 5 | F | 7 400 | SR | Y | N | Y | None | None |
| 5 | 3 | M | 34 200 | SR | Y | Y | Y | None | 10 |
| 6 | 5 | F | 3 900 | SR | Y | N | Y | 12p11.2‐p13.2 | 10, 21 |
| 7 | 5 | F | 77 800 | HR | Y | N | Y | None | None |
| 8 | 13 | F | 700 | HR | Y | N | Y | 12p11.2‐pter | None |
| 9 | 4 | M | 14 800 | SR | Y | Y | Y | None | 21 |
| 10 | 2 | M | 86 000 | HR | Y | N | Y | None | None |
| 11 | 3 | M | 14 000 | SR | Y | U | N | 6q22 | 21 |
| 12 | 3 | F | 39 200 | SR | Y | Y | Y | 11q13.3‐qter, 12p, 6q26‐qter | None |
| 13 | 2 | F | 159 000 | HR | N | NE | N | 12p | Xp |
| 14 | 7 | M | 8 400 | SR | Y | N | Y | 7q32‐qter | 10 |
| 15 | 6 | F | 37 500 | HR | Y | N | Y | None | Xq26‐qter |
| 16 | 2 | M | 5 100 | SR | Y | N | Y | None | None |
| 17 | 8 | M | 11 700 | HR | Y | N | Y | 11q21‐qter | 21q21‐qter, Xq21.3‐qter |
| 18 | 4 | F | 36 400 | HR | Y | N | Y | 12p | None |
| 19 | 8 | F | 10 100 | HR | Y | N | Y | 6q21‐q23 | 21 |
| 20 | 3 | M | 10 800 | HR | Y | N | Y | None | None |
| 21 | 4 | F | 8 100 | SR | Y | N | Y | 12p11‐p12 | None |
| 22 | 6 | M | 51 800 | HR | Y | N | Y | None | 21q22‐qter |
| 23 | 2 | F | 12 900 | HR | Y | N | Y | 1p34‐pter, 9p, 11q12, 12p12.1‐per, 16p, 17p | None |
| 24 | 3 | F | 16 700 | HR | Y | N | Y | 12p13 | None |
| Reh | NA | NA | NA | NA | NA | NA | NA | 3p21.1‐p21.3 | 21q21‐qter |
| KOPN41 | NA | NA | NA | NA | NA | NA | NA | 12p13.2‐pter | 21q21‐qter |
All cases were confirmed to have TEL–AML1 transcripts by reverse transcription–polymerase chain reaction. CR, complete remission; Dx, diagnosis; HR, high risk; NA, not applicable; NCI, National Cancer Institute; NE, not evaluable; SR, standard risk; U, unknown; WBC, white blood cell count.